US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Amicus Therapeutics, Inc.
< Previous
1
2
Next >
Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates
August 08, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics to Announce Second Quarter 2024 Financial Results on August 8, 2024
July 30, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product
June 04, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
May 09, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference
May 08, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
May 01, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
March 20, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
March 01, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
February 28, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
February 15, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
February 08, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
February 01, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
January 07, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
December 05, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
November 08, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
November 01, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023
October 27, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
October 03, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
October 02, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
September 28, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
September 01, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
August 29, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
August 21, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
August 15, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
August 08, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023
July 31, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
June 27, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
May 10, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FOLD
< Previous
1
2
Next >
